Initiatives to Advance the Implementation of "Cancer Genomic Medicine."
- GOOD HEALTH AND
WELL-BEING - INDUSTRY, INNOVATION AND
INFRASTRUCTURE
Issue
A uniform system for accessing "cancer genomic medicine" across Japan has not been established.
“Cancer genomic medicine,” which tailors treatments based on patients’ genomic profiles, is gaining global attention as a promising approach for delivering more effective care with minimal side effects.
In Japan, the government significantly increased its fiscal 2018 budget for cancer genomic medicine to six times the previous year’s allocation. Furthermore, the “Cancer Genomic Medicine Promotion Consortium,” comprising medical institutions, universities, pharmaceutical companies, and regulatory bodies, was launched to advance this initiative.
Despite these efforts, e-Solutions identified critical gaps: the inadequate development of a system ensuring equal access to cancer genomic medicine nationwide, and the lack of sustainable strategies and business models to support continuous treatment.
Approach
Promoting "gene testing services" in collaboration with a major manufacturer.
Through market analysis of the United States, a leading country in “cancer genomic medicine,” we examined the ideal framework and challenges for implementing “cancer genomic medicine” in Japan. Discussions were held with key stakeholders in the government to explore pathways for realizing such treatments domestically.
To enhance private-sector capacity for gene testing, we engaged with major manufacturers and supported the formulation and commercialization of “gene testing services” strategies aligned with national policies.